| 06/22 | Nicox Extraordinary General Meeting of July 11, 2022 | GL |
| 06/22 | Nicox Extraordinary General Meeting of July 11, 2022 | AQ |
| 06/15 | NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the E.. | PU |
| 06/15 | NICOX : How to participate in the Extraordinary shareholder meeting | PU |
| 06/14 | NICOX : 2022 Ordinary Shareholder Meeting | GL |
| 06/14 | NICOX : 2022 Ordinary Shareholder Meeting | GL |
| 06/03 | NICOX : 2022 Extraordinary Shareholder Meeting | GL |
| 06/03 | NICOX : 2022 Extraordinary Shareholder Meeting | AQ |
| 06/03 | Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In Novemb.. | MT |
| 06/03 | Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov.. | GL |
| 06/03 | Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov.. | AQ |
| 06/03 | Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial t.. | CI |
| 05/16 | Ophthalmology Group Nicox Appoints New CEO, Chairman | MT |
| 05/16 | Nicox Announces a New Governance Structure | GL |
| 05/16 | Nicox Announces a New Governance Structure | AQ |
| 05/16 | Nicox S.A. Announces Executive Changes | CI |
| 05/04 | NICOX : 2022 Ordinary Shareholder Meeting | GL |
| 05/04 | NICOX : 2022 Ordinary Shareholder Meeting | AQ |
| 05/02 | NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin.. | GL |
| 05/02 | NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin.. | AQ |
| 04/28 | Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Pr.. | AQ |
| 04/11 | Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma | AQ |
| 04/11 | Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma | CI |
| 03/03 | Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA .. | AQ |
| 03/03 | Ocumension Therapeutics Says Phase III Study of Eye Drops in China Yields Positive Resu.. | MT |
| 03/02 | Nicox Partner Fera Pharmaceuticals Wins US FDA's Orphan Drug Designation for Sickle Cel.. | MT |
| 03/02 | Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA .. | AQ |
| 03/01 | Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE.. | GL |
| 03/01 | Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZER.. | CI |
| 03/01 | Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE.. | GL |
| 02/23 | Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 C.. | AQ |
| 02/23 | Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 C.. | CI |
| 02/22 | France's Nicox Wins Japanese Patent for Dry Eye Disease Drug | MT |
| 02/22 | Nicox Granted New Patent for NCX 4251 in Japan | AQ |
| 02/21 | Nicox Receives New Chinese Patent For Ocular Hypertension Product | MT |
| 02/21 | Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039 | AQ |
| 02/21 | Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Form.. | CI |
| 02/08 | Nicox to Launch New Dry Eye Disease Study in 2023 | MT |
| 02/08 | Nicox's Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye | AQ |
| 02/08 | Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye | CI |
| 01/27 | Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 .. | AQ |
| 01/21 | Nicox Provides Fourth Quarter 2021 Business and Financial Highlights | AQ |
| 01/06 | NICOX : Half-year liquidity contract statement for NICOX | AQ |
| 01/05 | Nicox Secures European Patent For Allergic Conjunctivitis Treatment | MT |
| 01/05 | Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030 | AQ |
| 2021 | Nicox Screens First Patient in China in Late-Stage Trial For Glaucoma Treatment | MT |
| 2021 | Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T.. | AQ |
| 2021 | Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T.. | CI |
| 2021 | GLOBAL MARKETS LIVE : General Motors, JP Morgan, Pfizer, Novavax, Ford... | |
| 2021 | Nicox Appoints Novartis Executive as Chief Scientific Officer | MT |
| 2021 | Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-c.. | AQ |
| 2021 | Nicox Appoints Doug Hubatsch as New Chief Scientific Officer to Lead Clinical and Non-C.. | CI |
| 2021 | Nicox Raises $17 Million in Share Placement, Restructures Kreos Bond Financing Deal | MT |
| 2021 | Nicox Restructures Kreos Capital Bond Financing Agreement and Raises €15 Million in Pri.. | AQ |
| 2021 | Number of voting rrights as of November 30, 2021 | AQ |
| 2021 | Nicox Reports Positive Results For Dry Eye Treatment Trial | MT |
| 2021 | Nicox's Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path.. | AQ |
| 2021 | Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical T.. | CI |
| 2021 | Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe | AQ |
| 2021 | Nicox's NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the A.. | AQ |
| 2021 | Nicox?s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the A.. | CI |
| 2021 | Number of voting rightts as of October 31 | AQ |
| 2021 | NICOX : Provides Third Quarter 2021 Business and Financial Highlights | AQ |
| 2021 | NICOX : to present at the OIS Glaucoma Virtual Innovation Showcase | AQ |
| 2021 | NICOX : Launches New Corporate & Investor Website | AQ |
| 2021 | NICOX : Eye Drug Shows Retinal Cell Protection In Nonclinical Trial | MT |
| 2021 | NICOX : NCX 470 Shows Retinal Cell Protection in a Nonclinical Model | AQ |
| 2021 | Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induce.. | CI |
| 2021 | GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM... | |
| 2021 | NICOX : First Half 2021 Financial Results and Business Update | AQ |
| 2021 | Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 | CI |
| 2021 | Nicox S.A. Announces Retirement of José Boyer as Interim Head of R&D | CI |
| 2021 | GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis... | |
| 2021 | NICOX : Eye Drug Trial Fails To Meet Efficacy Endpoints | MT |
| 2021 | NICOX : Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
